Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Carlsbad, CA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Fair Oaks, CA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Fresno, CA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
San Diego, CA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Evansville, IN
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Madisonville, KY
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Madisonville, KY
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Shreveport, LA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Saginaw, MI
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Bayonne, NJ
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Bayonne, NJ
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Dallas, TX
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Dallas, TX
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Houston, TX
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
McAllen, TX
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated:  1/31/2014
Clinical Research Facility
mi
from
Virginia Beach, VA
Study of Oasis Ultra in Diabetic Foot Ulcers
A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Status: Enrolling
Updated: 1/31/2014
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  2/7/2014
Hanmi
mi
from
California, CA
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 2/7/2014
Hanmi
mi
from
California, CA
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Jacksonville, FL
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Miami, FL
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Marlton, NJ
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)
Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With DM: COACH-DM
Status: Enrolling
Updated:  2/14/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)
Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With DM: COACH-DM
Status: Enrolling
Updated: 2/14/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated:  2/18/2014
Clinical Research Facility
mi
from
Chula Vista, CA
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated: 2/18/2014
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated:  2/18/2014
Clinical Research Facility
mi
from
Overland Park, KA
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated: 2/18/2014
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated:  2/18/2014
Clinical Research Facility
mi
from
Louisville, KY
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes
Status: Enrolling
Updated: 2/18/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management
A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management
Status: Enrolling
Updated:  2/24/2014
Pediatric Endocrinology, Yale University
mi
from
New Haven, CT
A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management
A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management
Status: Enrolling
Updated: 2/24/2014
Pediatric Endocrinology, Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Little Rock, AR
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Encino, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Encino, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Escondido, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Escondido, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Huntington Beach, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
La Mesa, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
La Mesa, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Lancaster, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Lancaster, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Monterey, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Monterey, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
San Mateo, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
San Ramon, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
San Ramon, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Walnut Creek, CA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Hialeah, FL
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Hialeah, FL
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Hollywood, FL
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Hollywood, FL
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Jacksonville, FL
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Marietta, GA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Marietta, GA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Roswell, GA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Roswell, GA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Savannah, GA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Savannah, GA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Idaho Falls, ID
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Indianapolis, IN
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Council Bluffs, IA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Iowa City, IA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Topeka, KA
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 2/26/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Topeka, KA
Click here to add this to my saved trials